1. Kumar V, Abbas AK, Aster JC et al. Robbins & Cotran pathologic basis of disease. 10th ed. Elsevier, Philadelphia, PA 2021; 1379.
2.
Nangole FW, Agak GW. Keloid pathophysiology: fibroblast or inflammatory disorders? JPRAS Open 2019; 22: 44-54.
3.
Chike-Obi C, Cole P, Brissett A et al. Keloids: pathogenesis, clinical features, and management. Semin Plast Surg 2009; 23: 178-184.
4.
Betarbet U, Blalock TW. Keloids: a review of etiology, prevention, and treatment. J Clin Aesthetic Dermatol 2020; 13: 33-43.
5.
Wen P, Wang T, Zhou Y et al. A retrospective study of hypofractionated radiotherapy for keloids in 100 cases. Sci Rep 2021; 11: 3598.
6.
Wang W, Zhao J, Zhang C et al. Current advances in the selection of adjuvant radiotherapy regimens for keloid. Front Med 2022; 9: 1043840.
7.
Craig RDP, Pearson D. Early post-operative irradiation in the treatment of keloid scars. Br J Plast Surg 1965; 18: 369-376.
8.
Malaker K, Ellis F, Paine CH et al. Keloid scars: A new method of treatment combining surgery with interstitial radiotherapy. Clin Radiol 1976; 27: 179-183.
9.
Perez and Brady’s principles and practice of radiation oncology. 6th ed. Wolters Kluwer health – Lippincott Williams & Wilkins, Philadelphia 2013.
10.
Jiang P, Baumann R, Dunst J et al. Perioperative interstitial high-dose-rate brachytherapy for the treatment of recurrent keloids: feasibility and early results. Int J Radiat Oncol 2016; 94: 532-536.
11.
Guix B, Henrı́quez I, Andrés A et al. Treatment of keloids by high-dose-rate brachytherapy: A seven-year study. Int J Radiat Oncol 2001; 50: 167-172.
12.
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [Internet]. Bethesda (MD): U.S. Department of Health and Human Services; 2017 Nov 27.
13.
Anderson EM, David J, Phillips T et al. Interstitial high-dose-rate brachytherapy in the treatment of keloids: Moving toward a volumetric approach. Brachytherapy 2021; 20: 185-188.
14.
Klaassen CD, Casarett LJ, Doull J et al. Casarett and Doull’s toxicology: the basic science of poisons. 8th ed. McGraw-Hill Education, New York 2013; 1454.
15.
Ma S, Fang R, Chang WP et al. Heterogeneity in radiosensitivity of human diploid fibroblasts from keloids and normal skins. Cell Biol Int 1996; 20: 289-292.
16.
Haber AH, Rothstein BE. Radiosensitivity and rate of cell division: “law of Bergonié and Tribondeau”. Science 1969; 163: 1338-1339.
17.
Lee SY, Park J. Postoperative electron beam radiotherapy for keloids: Treatment outcome and factors associated with occurrence and recurrence. Ann Dermatol 2015; 27: 53.
18.
Fernandes J, Liao D, Dasgupta A et al. A single-institution review of the use of radiation in the adjuvant and definitive management of keloids. Clin Oncol 2024; 36: e163-167.
19.
Peng Q, Lu Y, Huang R et al. Should we do postoperative radiotherapy after keloid excision as soon as possible? A systematic review and meta-analysis. Aesthetic Plast Surg 2025; 49: 4671-4682.
20.
Guinot JL, Rembielak A, Perez-Calatayud J et al., GEC ESTRO. GEC-ESTRO ACROP recommendations in skin brachytherapy. Radiother Oncol 2018; 126: 377-385.
21.
Escarmant P, Zimmermann S, Amar A et al. The treatment of 783 keloid scars by iridium 192 interstitial irradiation after surgical excision. Int J Radiat Oncol 1993; 26: 245-251.
22.
Mankowski P, Kanevsky J, Tomlinson J et al. Optimizing radiotherapy for keloids: a meta-analysis systematic review comparing recurrence rates between different radiation modalities. Ann Plast Surg 2017; 78: 403-411.
23.
De Cicco L, Vischioni B, Vavassori A et al. Postoperative management of keloids: Low-dose-rate and high-dose-rate brachytherapy. Brachytherapy 2014; 13: 508-513.
24.
Vera Barragán V, Alonso García AI, Fernández García J et al. Perioperative interstitial high-dose-rate brachytherapy for keloids scar. J Contemp Brachytherapy 2022; 14: 29-34.
25.
Garg MK, Weiss P, Sharma AK et al. Adjuvant high dose rate brachytherapy (Ir-192) in the management of keloids which have recurred after surgical excision and external radiation. Radiother Oncol 2004; 73: 233-236.
26.
Manjunath K, Venkatesh M, Alva R et al. Efficacy of surgical excision and adjuvant high-dose rate brachytherapy in treatment of keloid: Our experience. J Cutan Aesthetic Surg 2021; 14: 337.
27.
Jiang P, Geenen M, Siebert FA et al. Efficacy and the toxicity of the interstitial high-dose-rate brachytherapy in the management of recurrent keloids: 5-year outcomes. Brachytherapy 2018; 17: 597-600.
28.
Hafkamp CJH, Lapid O, Dávila Fajardo R et al. Postoperative single-dose interstitial high-dose-rate brachytherapy in therapy-resistant keloids. Brachytherapy 2017; 16: 415-420.
29.
Gonzalez-Alaña I, Martin-Playa P, Aparicio-Elizalde L et al. Post-surgical brachytherapy in the treatment of keloids: a single-center study. J Contemp Brachytherapy 2025; 17: 153-159.
30.
Zhou W, Li B, Yin Y et al. Treatment outcomes of surgery followed by short-course every other day radiotherapy in keloid. Radiat Oncol 2024; 19: 91.
31.
Goutos I, Ogawa R. Brachytherapy in the adjuvant management of keloid scars: literature review. Scars Burns Heal 2017; 3. Available from: https://journals.sagepub.com/doi/10.1177/2059513117735483
32.
Hall EJ. Radiobiology for the radiologist. 5th ed. Lippincott Williams & Wilkins, Philadelphia (PA) 2000; 149.
33.
Nangole FW, Ouyang K, Anzala O et al. Does keloid histology influence recurrence? Am J Dermatopathol 2021; 43: 642-646.